Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03909412 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Study acronym: CarMob
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Sep 2026 → Aug 2027
See other at-risk trials from Hackensack Meridian Health

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Aug 2027
    • Eligibility criteria expanded, about 7 words
    • Publications: details revised at 19 of 24 entries
  2. Re-verified, no change to tracked fieldsv15
  3. Primary and study completion dates: Oct 2025 to Sep 2026v14
  4. Primary and study completion dates: Dec 2024 to Oct 2025v13
  5. Trial status: Suspended to Recruiting
    • Eligibility criteria expanded, about 40 words
    • Site details revised
    • Collaborators shortened, about 1 word
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Trial status: Recruiting to Suspended Sponsor's reason: Investigational Product Source Change
    • Site details revised
    v11
  2. Primary and study completion dates: Dec 2023 to Dec 2024v10
  3. Primary and study completion dates: Feb 2023 to Dec 2023
    • Site contact updated
    v9
  4. Primary and study completion dates: Jun 2022 to Feb 2023
    • Eligibility criteria expanded, about 6 words
    v8
  5. Primary and study completion dates: Mar 2022 to Jun 2022v7
  6. Primary and study completion dates: Mar 2021 to Mar 2022v6
  7. Re-verified, no change to tracked fieldsv5
  8. Start date changed from estimate of Sep 2019 to Oct 8, 2019v4
  9. Start date: Jun 2019 to Sep 2019v3
  10. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2019 to Jun 2019
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Trial Details
NCT Number NCT03909412
Lead Sponsor Hackensack Meridian Health
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov